The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...

Am J Health Syst Pharm. 2007;64(11):1148-1152. Health care organizations around the nation have been working to reduce the use of meperidine as a first-line agent for pain management. Despite the ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

Richard Silverman highlights some of the research that led to the discovery of a novel analgesic drug, while Bob Rappaport discusses his role in the regulation of analgesic drug products.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.